Sign Up to like & get
recommendations!
0
Published in 2018 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2018.07.010
Abstract: Ponatinib (ICLUSIG, Takeda; Osaka, Japan) is an oral third-generation tyrosine kinase inhibitor (TKI) approved by US Food and Drug Administration in 2012 used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic…
read more here.
Keywords:
associated ponatinib;
nevi associated;
melanocytic nevi;
eruptive melanocytic ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Melanoma research"
DOI: 10.1097/cmr.0000000000000797
Abstract: Eruptive melanocytic nevi (EMN) describes the sudden onset of cutaneous nevi over weeks or months. Such a clinical event is generally seen in young adult patients and may be related to several possible causes. We…
read more here.
Keywords:
eruptive melanocytic;
patient;
melanocytic nevi;
paraneoplastic phenomenon ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Lupus"
DOI: 10.1177/0961203317751064
Abstract: Sir, The sudden development of multiple melanocytic nevi over weeks to months is an uncommon phenomenon known in the literature as eruptive melanocytic nevi (EMN), and it has been associated with a number of conditions,…
read more here.
Keywords:
melanocytic nevi;
dermatology;
eruptive melanocytic;
cutaneous lupus ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Acta dermato-venereologica"
DOI: 10.2340/00015555-2475
Abstract: Development of eruptive melanocytic naevi (EMN) is an uncommon phenomenon characterized by the sudden onset of hundreds of melanocytic naevi. EMN have been described after severe bullous diseases and administration of immunosuppressive drugs (1–5). The…
read more here.
Keywords:
radotinib therapy;
eruptive melanocytic;
myeloid leukaemia;
patients chronic ... See more keywords